Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?
Authors:
- 9 September 2010
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 12 (6) , 450-463
Abstract
The renin-angiotensin-aldosterone system (RAAS) plays an important role in blood pressure control and volume homeostasis. Inappropriate activation of the RAAS has been implicated in the pathogenesis of hypertension and related cardiovascular disease. Several classes of agents that block RAAS signaling have been shown to be effective antihypertensives and to have cardioprotective and renoprotective properties. Because blockade of the RAAS is incomplete with any of the currently available monotherapies, combinations of these agents have been tested and shown to provide additional clinical benefit in patients with hypertension and various forms of cardiovascular and renal disease.Keywords
This publication has 62 references indexed in Scilit:
- Efficacy of Spironolactone Therapy in Patients With True Resistant HypertensionHypertension, 2010
- Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 2009
- Aldosterone Antagonists for Preventing the Progression of Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)Clinical Journal of the American Society of Nephrology, 2009
- Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 RatsHypertension, 2008
- Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysisCurrent Medical Research and Opinion, 2008
- Effect of Spironolactone on Blood Pressure in Subjects With Resistant HypertensionHypertension, 2007
- Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in HypertensionHypertension, 2005
- Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)Hypertension, 2002
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999